| Literature DB >> 24523764 |
Babak Nakhostin-Roohi1, Zahra Niknam2, Nasrin Vaezi2, Sadollah Mohammadi3, Shahab Bohlooli3.
Abstract
Methylsulfonylmethane (MSM) is a sulfur-containing compound commonly found in diet and known to reduce oxidative stress. This trial was conducted to determine whether single dose supplementation with MSM attenuates post-exercise oxidative stress in healthy untrained young men. Sixteen untrained men volunteered for this study. Participants were randomized in a double-blind placebo-controlled fashion into 2 groups: Methylsulfonylmethane (MSM) (n = 8) and placebo (n = 8). The participants took supplementation or placebo before running on treadmill for 45 min at 75% VO2max. The MSM supplementation was prepared in water as 100 mg/ kg body weight. The placebo group received water. Serum Malondealdehyde (MDA), uric acid, bilirubin, protein carbonyl (PC) and plasma vitamin E levels were determined as the markers of oxidative stress. Plasma GSH (reduced Glutathione) and total antioxidant capacity (TAC) were measured as markers of plasma antioxidant system. MSM supplementation successfully lowered serum PC 2 and 24 h after exercise. Plasma TAC in MSM group was higher at 24 h after exercise. Serum level of uric acid and bilirubin were significantly low immediately after exercise in MSM supplemented group. There was no significant difference between groups in terms of plasma GSH level. These results complement earlier studies showing anti-oxidant effect of MSM and suggest that single dose oral supplementation with MSM lowers exercise induced oxidative stress in healthy untrained young men, but is not adequate to significantly affect plasma GSH level.Entities:
Keywords: Antioxidant; Bilirubin; GSH; MDA; MSM; Protein carbonylation; TAC; Uric acid
Year: 2013 PMID: 24523764 PMCID: PMC3920715
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Comparison of subjects’ characteristics in MSM and placebo groups
| MSM | Placebo |
| |
|---|---|---|---|
| Age (years) | 20.1 ± 1.4 | 19.5 ± 0.8 | 0.69 |
| Height (cm) | 170.9 ± 5.2 | 176.3 ± 5.2 | 0.48 |
| Weight (kg) | 70.9.± 8.1 | 74.1 ± 10.5 | 0.81 |
| Body mass index (kg.m-2) | 24.2 ± 2.4 | 23.9 ± 3.3 | 0.94 |
| Body fat (%) | 9.6 ± 3.7 | 9.8 ± 3.9 | 0.97 |
| VO2max (ml.kg-1.min-1) | 39.9 ± 3.3 | 40.0 ± 4.4 | 0.98 |
Values are mean ± SEM (n=8); VO2max maximal oxygen consumption. * Mean values was not significantly different between MSM and Placebo
Dietary Analysis in MSM and placebo groups
| Placebo | MSM | P-value* | |
|---|---|---|---|
| Energy (Kcal) | 2009 ± 241 | 1994 ± 231 | 0.992 |
| Carbohydrate (g) | 291 ± 62 | 287 ± 64 | 0.996 |
| Protein (g) | 98 ± 28 | 74 ± 19 | 0.751 |
| Fat (g) | 50 ± 13 | 62 ± 18 | 0.800 |
| Vitamin A(mg) | 296 ± 115 | 326 ± 181 | 0.719 |
| Vitamin C (mg) | 38 ± 18 | 37 ± 22 | 0.928 |
| Vitamin E (mg) | 14 ± 9 | 17 ± 12 | 0.416 |
Data are means ± standard deviations of mean (n=8). * Mean values was not significantly different between MSM and Placebo.
Values of GSH, Uric Acid and Vitamin E in serum or plasma of subjects before and after acute bout of exercise in Placebo and Methylsulfonylmethane supplemented (MSM) groups
| Group | Baseline (-2 h) | Pre | PE | 2 PE | 24 PE | |
|---|---|---|---|---|---|---|
| MDA (µM/L) | P | 2.53±0.18 | 2.76±0.23 | 3.1±0.43 | 2.72±0.32 | 2.69±0.18 |
| M | 2.37±0.29 | 2.00±0.18* | 2.55±0.19 | 1.95±0.11* | 2.29±0.22 | |
| GSH (µM/L) | P | 9.43±0.53 | 9.78±0.88 | 8.24±0.22 | 8.86±0.24 | 8.82±0.17 |
| M | 8.75±0.33 | 9.42±0.46 | 8.35±0.18 | 8.84±0.43 | 9.80±0.71 | |
| Uric Acid (mg/dL) | P | 2.45±0.15 | 2.32±0.30 | 3.16±0.16+ | 2.93±0.15+ | 2.53±0.11 |
| M | 2.06±0.11 | 2.40±0.11 | 2.63±0.06* | 2.73±0.09+ | 2.59±0.17+ | |
| Vitamin E (µg/mL) | P | 10.98±0.53 | 10.94±0.72 | 10.76±0.83 | 12.39±0.74 | 11.26±0.97 |
| M | 9.87±0.49 | 9.98±0.83 | 10.69±0.96 | 9.46±0.31* | 10.13±0.27 |
Values are means ±SEM (n=8)* Mean value was significant vs. placebo group at the same time point; + Mean value was significant vs. Pre value; Pre: pre exercise; PE: Post Exercise; GSH: Reduced Glutathione;
Figure 1Serum PC content after acute bout of exhaustive exercise under MSM or placebo administration. Values represent means ± SEM (n = 8). ** p < 0.001 significant difference in change in MSM vs. Placebo; * p < 0.05 significant difference in change in MSM vs. Placebo; # p < 0.05 significant difference from pre-exercise values, same treatment. Pt pre-treatment (base line), Pre pre-exercise, Post post-exercise
Figure 2Plasma TAC level after acute bout of exhaustive exercise under MSM or placebo administration. Values represent means ± SEM (n = 8). * p < 0.01 significant difference from pre exercise values, same treatment; # p < 0.05 significant difference in change in MSM vs. Placebo group. Pt pre-treatment (base line), Pre pre-exercise, Post post-exercise
Figure 3Serum total bilirubin level after acute bout of exhaustive exercise under MSM or placebo administration. Values represent means ± SEM (n = 8). * p < 0.05 significant difference in change in Placebo from MSM and pre exercise values. Pt pre-treatment (base line), Pre pre-exercise, Post post-exercise